ROLE OF ACCESSORY PROTEINS OF HTLV-1 IN VIRAL REPLICATION, T CELL ACTIVATION, AND CELLULAR GENE EXPRESSION

Bindhu Michael 1, Amrithraj Nair 1 and Michael D. Lairmore 1,2,3

1 Center for Retrovirus Research and Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio 43210, 2 Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio 43210, 3 Comprehensive Cancer Center, The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio 43210

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. HTLV-1 accessory proteins encoded by the pX region
4. pX ORF I p12I
   4.1. Biochemical characteristics of p12I: features of a signaling molecule
   4.2. Subcellular localization of p12I and interactions with cellular proteins
   4.3. Role of 12I in regulation of viral infectivity in vitro and in vivo
   4.4. Role of 12I in calcium-mediated T cell activation
   4.5. Putative role of p12I variants in disease
5. pX ORF II p30II
   5.1. Biochemical characteristics of p30II: features of a transcription modulator
   5.2. Role of p30II in modulating HTLV-1 LTR-mediated transcription
   5.3. Role of p30II in modulating cellular gene transcription
   5.4. Potential role p30II in T cell activation
   5.5. Genes Modulated p30II in apoptosis, cell cycle and cell adhesion
6. pX ORF II p13II
   6.1. Biochemical characteristics of p13II: mitochondrial targeting
   6.2. p13II alteration of mitochondrial morphology and inner membrane potential
   6.3. p13II cellular protein interactions
7. Accessory gene products of related deltaretroviruses
8. Perspective
9. Acknowledgements
10. References

1. ABSTRACT

Human T-cell lymphotropic virus type 1 (HTLV-1), causes adult T cell leukemia/lymphoma (ATLL), and initiates a variety of immune mediated disorders. The viral genome encodes common structural and enzymatic proteins characteristic of all retroviruses and utilizes alternative splicing and alternate codon usage to make several regulatory and accessory proteins encoded in the pX region (pX ORF I to IV). Recent studies indicate that the accessory proteins p12I, p27I, p13II, and p30II, encoded by pX ORF I and II, contribute to viral replication and the ability of the virus to maintain typical in vivo expression levels. Proviral clones that are mutated in either pX ORF I or II, while fully competent in cell culture, are severely limited in their replicative capacity in a rabbit model. These HTLV-1 accessory proteins are critical for establishment of viral infectivity, enhance T-lymphocyte activation and potentially alter gene transcription and mitochondrial function. HTLV-1 pX ORF I expression is critical to the viral infectivity in resting primary lymphocytes suggesting a role for the calcineurin-binding protein p12I in lymphocyte activation. The endoplasmic reticulum and cis-Golgi localizing p12I activates NFAT, a key T cell transcription factor, through calcium-mediated signaling pathways and may lower the threshold of lymphocyte activation via the JAK/STAT pathway. In contrast p30II localizes to the nucleus and represses viral promoter activity, but may regulate cellular gene expression through p300/CREB or related co-activators of transcription. The mitochondrial localizing p13II induces morphologic changes in the organelle and may influence energy metabolism infected cells. Future studies of the molecular details HTLV-1 "accessory" proteins interactions will provide important new directions for investigations of HTLV-1 and related viruses associated with lymphoproliferative diseases. Thus, the accessory proteins of HTLV-1, once thought to be dispensable for viral replication, have proven to be directly involved in viral spread in vivo and represent potential targets for therapeutic intervention against HTLV-1 infection and disease.

2. INTRODUCTION

Human T-cell lymphotropic virus type 1 (HTLV-1), the first described human retrovirus, causes adult T cell leukemia/lymphoma (ATLL), an aggressive CD4-T cell malignancy and initiates a variety of immune mediated disorders including HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a chornic neurodegenerative
Role of accessory proteins of HTLV-1

Figure 1. Diagrammatic illustration of HTLV-1 genome with nucleotide location (#) shown for spliced sites. Proteins produced or predicted from RNA shown on right with ORF origin shown as superscript.

Figure 1. Diagrammatic illustration of HTLV-1 genome with nucleotide location (#) shown for spliced sites. Proteins produced or predicted from RNA shown on right with ORF origin shown as superscript.

The genome of HTLV-1 encodes structural (e.g., group specific core antigens, Gag) and enzymatic proteins (e.g., reverse transcriptase, RT) characteristic of all retroviruses. Additionally, HTLV-1, a complex retrovirus, utilizes alternative splicing mechanism and internal initiator codons, to make several regulatory and accessory proteins encoded by four open reading frames (ORFs) of the pX region (pX ORF I to IV) between the env gene and the 3' long terminal repeat (1, 13). ORF IV of HTLV-1 encodes the well-characterized Tax transactivating protein, while the ORF III encodes Rex, a key regulator of viral RNA transport. Tax is a 40 kD nuclear-localizing phosphoprotein, which interacts with cellular transcription factors to activate transcription from the viral promoter (Tax responsive element, TRE), as well as the enhancer elements of various cellular genes associated with host cell proliferation (4-18). Rex is a 27 kD, nuclear-localizing phosphoprotein that functions to enhance nuclear export of unspliced or singly spliced viral RNA thus contributing to virus propagation (19-23). Both Tax and Rex have been the subject of recent reviews (15-17, 19, 24-27). In this review we focus on the important role that accessory proteins have in HTLV-1 replication and pathogenesis. Base on recent studies it has become clear that these proteins are, in fact, essential for the virus life cycle and may determine disease outcome associated with HTLV-1 infection.

3. HTLV-1 ACCESSORY PROTEINS ENCODED BY THE pX REGION

The HTLV-1 pX genome region includes ORF I and II that produce alternatively spliced forms of mRNA, which encode four accessory proteins, p12I, p27I, p13II, and p30II (Figure 1) (28-31). pX ORF I mRNA is produced by alternative splicing events that combine the second exon of Tax with additional downstream sequences and encodes p27I (152 amino acids long) and p12I (99 amino acid long). p12I can be translated from a singly spliced message produced by direct splicing of nucleotide 119 to the splice acceptor at position 6383 or by initiation at an internal methionine codon in the p27I ORF I (32). p12I is thought to be preferentially expressed from the p27I mRNA since transfection of expression plasmids containing HA1-tagged versions of either the full-length p27I cDNA or the cDNA for the singly spliced p12I produced only the smaller p12I protein (30). However, using in vitro transcription-translation systems, Ciminale et al. (32) produced p27I from the doubly spliced mRNA. Therefore, removal of the internal p12I AUG start codon could yield detectable levels of p27I. Interestingly, Pique et al. (33) demonstrated production of cytotoxic T cells in HTLV-1-infected subjects that were reactive against peptides representing all putative pX accessory proteins, including p27I. The accessory proteins encoded by pX ORF II of HTLV-1 are produced from two alternatively spliced mRNAs. The larger protein, p30II, is encoded by a doubly spliced message including the first and second exon of Tax spliced to the splice acceptor site at position 6383 (31). p13II, the smaller protein contains the C-terminal 87 amino acids of p30II and is produced from a singly spliced message by splicing of the first Tax exon directly to the splice acceptor at position 6383 or translated from an internal methionine codon within p30II (30, 31). HTLV-1 accessory proteins were originally thought to be dispensable for viral
Role of accessory proteins of HTLV-1

Figure 2. Diagram of key HTLV-1 accessory proteins with known motifs. PxxP = proline motifs predicted to be SH3 binding domains, LZip = leucine zipper like motif, DxxLL = putative AP-1 adaptor binding motif, IL-2R = region of IL-2 receptor binding, PxIxIT = calcineurin binding motif, NLS = nuclear localization motif, MTS = mitochondrial targeting signal.

P12I

<table>
<thead>
<tr>
<th>TM-1</th>
<th>TM-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>PxxP</td>
<td>PxxP</td>
</tr>
<tr>
<td>LZip</td>
<td>DxxLL</td>
</tr>
<tr>
<td>IL-2R</td>
<td>LZip</td>
</tr>
</tbody>
</table>

P30II

| SS - SR - DS |
| NLS |

P13II

| MTS |

4. pX ORF I p12I

4.1. Biochemical Characteristics of p12I: Features of a Signaling Molecule

HTLV-1 p12I is a highly hydrophobic protein, which contains a significant percentage of leucine (32%) and proline (17%) residues. Hydropathy and immunogenicity plots demonstrate a minimal number of soluble regions and two putative transmembrane domains extending from amino acid 12 to 30 and amino acid 40 to 47 (51, 55), which overlap with two predicted leucine zipper motifs that form alpha-helices. These distinct structural features could contribute to membrane localization or homo-oligomerization of the protein (Figure 2). Immunoprecipitation and immunoblot analysis have demonstrated that p12I indeed forms at least dimers, if not oligomers (48). However, helix-breaking proline residues within the predicted leucine zippers suggest that these may not be functional leucine zippers. Additionally, p12I contains four predicted SH3-binding motifs (Figure 2). Typically, SH3-binding motifs in cellular signaling proteins are proline rich with a minimal core of PXXP and are often preceded by an arginine residue at +2 (56). Interestingly, amino acids 8 to 11 and 70 to 74, encoding the first and third PXXP motifs of p12I are highly conserved among viral strains, suggesting a possible role for these domains in the function of p12I. We have described another conserved
It cooperates with E5 and is required for the interaction, but this region alone is not sufficient for binding (59). Although this association appears to be required for the E5-mediated transformation of epithelial cells, there is no clear correlation with the weak transforming ability of p12, the p12-16K interaction and cooperative transformation with BPV E5. Thus, the functional significance of the p12-16K interaction remains to be determined. Interestingly, Nef, a key accessory protein of simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV), binds the catalytic subunit NBP-1 of the ATPase (60). NBP-1 association of Nef mediated by the Nef C-terminal flexible loop is critical for Nef-dependent internalization of CD4 and viral infectivity (61).

Analogous to E5, p12 also associates with immature form of IL-2 receptor β and γ chain when transiently co-expressed, resulting in reduced surface expression of the receptor chains (62). The IL-2R binding region of p12 mapped to the central proline-rich region (amino acids 37 to 47), which lies directly in front of the C-terminal proposed transmembrane domain of the protein. The p12-binding site on the IL-2R chain overlaps with the binding site for JAK kinases 1 and 3 and the adapter protein Shc. p12 does not influence JAK3 kinase activity directly, however it is considered to be accountable for the modest increase in STAT5 DNA binding activity in 293T cells co-transfected components of the IL-2 receptor signaling complex and in primary human lymphocytes transduced with a lentiviral p12-expressing vector (63). As a consequence, p12-expressing cells displayed a decreased requirement for IL-2 to induce proliferation during suboptimal stimulation with anti-CD3 and anti-CD28 antibodies (63). However, peripheral blood derived lymphocyte cell lines immortalized by a HTLV-1 proviral clone ablated for pX ORF I expression, ACH.p12, have intact IL-2 receptor signaling pathways (64). A possible explanation for these conflicting observations is that p12 may modestly activate IL-2 receptor pathways during the early stages of HTLV-1 infection before immortalization. Nevertheless, p12 does not appear to be necessary for the activation of the IL-2R-associated Janus kinases, JAK1 and JAK3, or their downstream effectors STAT3 and STAT5, after immortalization. Collectively, these studies indicate that p12 may induce STAT activity to confer a growth advantage to infected cells during the early stages of infection, before immortalization. Future studies are necessary to elucidate the JAK3-independent pathway p12 uses to induce STAT5 activation.

HTLV-1 p12 shares sequence homology with the bovine papilloma virus (BPV) E5 protein and Epstein-Barr virus (EBV) LMP-1 protein (58). The region of highest homology starts after the first transmembrane domain and extends into the second. Like E5, HTLV-1 p12 also binds to the 16 kD subunit of the vacuolar H+-ATPase (16K). Although p12 itself cannot induce the transformation of mouse C127 fibroblasts, it cooperates with E5 and potentiates the transforming ability of E5 (58). Further study to map the motif in p12 associated with 16K protein revealed that a central proline-rich region between aa 36-48 is required for the interaction, but this region alone is not sufficient for binding (59). Although this association appears to be required for the E5-mediated transformation of epithelial cells, there is no clear correlation with the weak transforming ability of p12, the p12-16K interaction and cooperative transformation with BPV E5. Thus, the functional significance of the p12-16K interaction remains to be determined. Interestingly, Nef, a key accessory protein of simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV), binds the catalytic subunit NBP-1 of the ATPase (60). NBP-1 association of Nef mediated by the Nef C-terminal flexible loop is critical for Nef-dependent internalization of CD4 and viral infectivity (61).
Role of accessory proteins of HTLV-1

lentiviral vector. These results suggest that p12I might help the virus escape immune surveillance by down regulating MHC-I surface expression. However, levels of MHC-I and II were similar between T-lymphocytes immortalized with the wild type and p12-mutant HTLV-1 molecular clones (ACH and ACH.p12 respectively), indicating that p12-mediated modulation of MHC-I surface expression likely occurs only during the early stages of infection (64). Intriguingly, the accessory proteins p10 and p11 of HTLV-2 also associate with MHC-I, however these do not bind to either 16K or IL-2Rβ or γ (66). Additionally, HIV-1 Nef also binds to and down regulates the cell surface expression of MHC-I and is believed to contribute to immune evasion by HIV-1 (67). However, down regulation of MHC-I of virus-infected cells does not explain the early loss of infectivity of a molecular clone of HTLV-1 that lacks ORF I expression, as virus infection is blocked as early as 1 week post-inoculation, before a possible active immune response occurs (43). Future studies of early virus replication immediately after inoculation of virus infected cells in animal models might provide evidence to whether p12I indeed down regulates MHC-I expression on infected PBMC in vivo and actively contributes to viral spread or persistence.

In addition, p12I associates with two ER-resident calcium-binding proteins, calreticulin and calnexin (55) and the calcium/calmodulin-dependent serine/threonine phosphatase, calcineurin (35). Calreticulin, a highly conserved and ubiquitous protein, serves as one of the major calcium-binding proteins in the ER, participates in calcium signaling, and has been linked to activation of the transcription factor nuclear factor of activated T cells (NFAT) (68). Through protein-protein interactions, calcineurin regulates transcriptional activation of NFAT by triggering the dephosphorylation and subsequent nuclear translocation of NFAT, which results in transactivation of NFAT-inducible cytokine genes including interleukin-2 (69-71). It would be advantageous for a virus to target such conserved proteins to dysregulate calcium signaling pathways to activate and modulate NFAT in infected T lymphocytes.

4.3. Role of 12I in Regulation of Viral Infectivity in vivo

Earlier reports showed that deletion of pX ORF I from HTLV-1 infectious molecular clones did not affect the viral infectivity and primary lymphocyte transformation mediated by HTLV-1 infection in vitro (34, 72). In contrast, our research group demonstrated that selective elimination of pX ORF I from the molecular clone ACH resulted in dramatically reduced viral infectivity in vivo (43). Rabbits inoculated with ACH.p12, harboring selective mutations that abolish the expression of pX ORF I mRNA, failed to establish persistent infection as indicated by reduced anti-HTLV-1 antibody responses, failure to demonstrate viral p19 antigen production in PBMC cultures, and only transient detection of provirus by PCR (43). A major difference between these in vitro and in vivo studies is that standard in vitro co-culture techniques used to transmit virus to naive PBMC utilize target cells stimulated by IL-2 and mitogen. However, in vivo the majority of circulating and tissue-associated lymphocytes are nondividing.

In support of these findings, using co-culture assays that would allow transmission of the virus to resting primary lymphocytes, our group demonstrated that pX ORF I mRNA is critical for viral infectivity in non-activated/quiescent PBMCs in vitro (42). In this study, HTLV-1 was transmitted by co-culturing naive PBMCs with three different virus producing cells, including HTLV-1 immortalized cell lines, ACH transfected 293 T cells and newly infected PBMCs, in the absence of exogenous stimuli to more accurately reflect the virus-cell interactions during the natural infection. Under these conditions, a significant decrease in viral infectivity of ACH.p12 producer cells was detected in primary lymphocytes. More importantly, viral infectivity was restored upon addition of IL-2 and mitogen to the co-cultured PBMCs (42). These data provided the first evidence that HTLV-1 p12I is required for optimal viral infectivity in nondividing primary lymphocytes and suggested a role of p12I in T-lymphocyte activation and in the early stage of viral infection. Analogously, studies of HIV-1 Nef indicate that the accessory protein is dispensable for transmission of the virus to activated target cells in vitro but is required for viral infectivity in nondividing lymphocytes (73-75).

4.4. Role of 12I in Calcium-Mediated T Cell Activation

Reports from our laboratory illustrated that p12I expression in Jurkat cells results in ~20-fold activation of NFAT dependent gene expression, while AP-1 or NF-κB-mediated transcription remained unchanged (36). p12I specifically activates NFAT in synergy with Ras/MAP kinase activation stimulated by the phorbol ester, PMA. By inhibition of proximal signaling molecules, such as phospholipase C-γ (PLC-γ) and LAT, as well as distal signals, including calcineurin and NFAT, the function of p12I was mapped to be between PLC-γ and calcineurin (36). p12I mediated NFAT activation was dependent on cytosolic calcium since this function was abolished by BAPTA-AM treatment. Importantly, p12I functionally substituted for thapsigargin, which specifically depletes the ER calcium store by blocking the ER calcium ATPase. Therefore, HTLV-1 p12I was found to activate NFAT-mediated transcription in lymphoid cells in a calcium-dependent manner. Indeed, p12I expression increases the base-line cytoplasmic calcium concentration in Jurkat T cells. This basal elevated calcium is likely secondary to reduced ER stores calcium content and subsequently higher extracellular calcium entry (37). Both the calcium channel on ER membranes, IP3R, and the calcium channels on plasma membranes, calcium release activated calcium channels (CRAC), contribute to the p12I mediated NFAT activation, strongly indicating the modulation role of p12I on calcium homeostasis.

The localization of p12I to the ER appears to be essential for NFAT activation, since diffusely localizing p12I truncation mutants were unable to activate NFAT, and partially restored the ability to activate NFAT when redirected to ER by addition of ER localization signal (76). p12I colocalizes with the ER-resident, calcium-binding
Role of accessory proteins of HTLV-1

proteins calreticulin and calnexin, which are involved in multiple cellular functions including calcium homeostasis, protein folding, as well as integrin mediated signaling pathways (55). The direct binding between calreticulin and p12I does not correlate with the NFAT activation since expression of calreticulin dramatically reduced p12I-induced NFAT activation independent of direct calreticulin-p12I interaction (37). Future studies are necessary to identify the biological significance of this protein-protein interaction in HTLV-1 infection and pathogenesis.

Interestingly, expression of p12I increased cytosolic calcium, indicating that HTLV-1 p12I induces release of calcium from the ER to activate NFAT (37), which would be an advantage for the virus during the early stages of HTLV-1 infection. Interestingly, this is similar to the function of a cellular protein CAML (Ca\(^{2+}\)-modulating cyclophilin ligand), which also contain two putative transmembrane domains like p12I, colocalizes with calreticulin in the ER, induces calcium release from the ER and leads to NFAT activation (77). In addition, p12I mediated increase in NFAT activity could cause complete activation of cellular stimuli that would normally induce only partial activation of T cells (e.g., through AP-1). These stimuli could be triggered by cytokines or chemokines released from infected neighboring cells or by direct contact between viral envelope proteins and certain cell surface receptors on newly targeted lymphocytes prior to viral entry (78).

Expression of NFAT induces a highly permissive state to overcome the blockade at reverse transcription and permitted HIV replication in primary CD4\(^+\) T cells, therefore it is possible that p12I causes T cells to be hypersensitive to T cell receptor and CD28 stimulation and thus highly permissive for subsequent viral infection. Interestingly, susceptibility of these cells to HIV infection could be restored by mitogen treatment, likely due to the phytohemagglutinin-induced upregulation of NFAT activity. This is similar to earlier reports from our laboratory, proline residues in these motifs were mutated into alanine residues to test the role of PXXP motifs in p12I-mediated NFAT activation. Interestingly, the third SH3 binding domain (PXXP motif). SH3 binding domain has been demonstrated to be important for protein-protein interaction and the PXXP motif in HIV Nef was found to be necessary for Nef-mediated NFAT activation and viral infection (85-87). In a recent report from our laboratory, proline residues in these motifs were mutated into alanine residues to test the role of PXXP motifs in p12I-mediated NFAT activation. Interestingly, the third SH3 binding domain (aa 70-73) was responsible for the negative effect of region aa 70-86 on NFAT activation (35, 76). Besides, mutations in the first two PXXP motifs (aa 8-11 and 35-38) caused only minimal changes in NFAT activation, while mutations in the last PXXP motif (aa 90-93) in the second positive region (aa 86-99), enhanced the NFAT activation. Future studies are necessary to elucidate the functional significance of specific residues within the PXXP motifs of p12I in NFAT activation.

We have demonstrated the role of the highly conserved calcineurin binding motif PSLP(I/L)T of p12I in its binding to calcineurin (35). Interestingly, p12I competes with NFAT for calcineurin binding as evidenced by the calmodulin bead pull-down experiments. More strikingly, alanine substitution mutations in PSLP(I/L) caused more NFAT nuclear translocation and increased NFAT transcriptional activity (~2-fold) than wild type p12I in a reporter gene assay (35). Interestingly, PSLP (I/L)T calcineurin binding site is within the aa 70–86 negative region and third PXXP motif which was responsible for the negative effect of region aa 70-86 on NFAT activation. Additionally, NFAT-inhibitory function of the PSLP(I/L)T motif in p12I was verified to be not from the inhibition of calcineurin phosphatase activity. PSLP(I/L)T is homologous to the conserved functionally critical calcineurin-binding motif (PXXPTT) in the N-terminal regulatory domain of NFAT, which binds both inactivated and activated calcineurin (88). Many calcineurin-binding
Role of accessory proteins of HTLV-1

proteins such as the anti-apoptotic protein Bcl-2, calcineurin B homologous protein, a kinase anchoring protein AKAP79, and myocyte-enriched calcineurin-interacting protein I inhibit either calcineurin phosphatase activity or its substrate NFAT transcriptional activity (89-91). However, PXLXT motif mediated binding itself does not inhibit the catalytic activity of calcineurin, because NFAT activation requires enzymatic activity of calcineurin as well as binding via this motif. Not surprisingly, p12I binding to calcineurin via a motif similar to PXLXT did not inhibit calcineurin catalytic activity but instead influenced NFAT and calcineurin interaction by competing for binding with NFAT similar to artificial peptides representing this motif (88).

Due to the existence of a calcineurin-binding motif in p12I, p12I may have at least two regulatory actions to modulate NFAT activation: (1) positive modulation by increasing cytosolic calcium concentration from ER stores and (2) negative modulation by calcineurin binding. It is unclear why p12I has two regulatory functions for NFAT transcriptional activity. It is notable that Bcl-2 has these similar properties like p12I, however the functional relationship between calcium release from the ER and calcineurin binding of Bcl-2 is also still unresolved. Bcl-2 maintains calcium homeostasis and prevents apoptosis by localizing not only at the mitochondrial membrane but also in the ER membranes (92, 93). p12I may function like Bcl-2 at the ER membrane, acting like an ion channel protein to increase ER calcium permeability. Like Bcl-2, p12I may affect apoptosis in HTLV-1-infected T cells. Another ER membrane protein, CAML that activates NFAT by interacting with cyclophilin (77). Overall, p12I interacts with calcineurin, an important regulator of NFAT signaling, via a highly conserved PSLP(I/L)T motif, to further T cell activation, an important antecedent to effective viral infection, via a calcium/calcineurin/NFAT pathway.

4.5. Putative Role of p12I Variants in Disease

Factors determining the progression from asymptomatic state to HAM/TSP and the contribution of viral factors are not fully understood. Recent studies aimed to identify sequence variation/ viral strains that are neuropathogenic suggest a possible role for p12I in the pathogenesis of HAM/TSP. The proteasome destabilization of viral proteins is thought to be an intracellular defense mechanism against viral infection (94, 95). Lysine is a known target for covalent binding of ubiquitin (94-96) and the metabolic instability p12I is mediated in part by ubiquitylation at a single lysine residue at position 88 and subsequent proteosomal degradation, as well as by destabilizing residues at its amino terminus (48). Interestingly, earlier analysis of p12I ORF in 21 HTLV-1 strains from different geographical areas (97) had demonstrated that p12I amino acid sequence is highly conserved and that, arginine residue is found more frequently at position 88 while the less frequent lysine carrying allele was found only in some TSP-HAM cases. Trovato et al. (48) extended this information by studying an additional 32 ex vivo samples from healthy carriers, TSP-

HAM patients, ATLL patients and families in which both diseases occur, and confirmed that the lysine residue is found only in patients with TSP/HAM, irrespective of geographical locations, suggesting that a selective pressure over p12I might occur in the host. However, lysine residue at position 88 in p12I was not found in all HAM/TSP patients. It is hypothesized that the reduced stability of p12I in HAM/TSP patients due to this sequence variation may facilitate generation of a viral-specific CTL response, since degradation of p12I would alleviate the reduction of MHC class I molecules at the cell surface (98).

Martins et al. extended these observations further to verify whether the presence of lysine at position 88 could be used as a marker of progression to HAM/TSP, by analyzing 37 HAM/TSP patients and 40 asymptomatic carriers at different stages of infection (99). Interestingly, in this study, lysine residue at position 88 of p12I did not appear to be a universal diagnostic marker for HTLV-1-associated neurological disease, since this phenotype was found not only in HAM/TSP patient (1 out of 37), but also in asymptomatic HTLV-1 carrier (1 out of 40) who did not develop neurologic signs for 5 years (99). Even though this study analyzed a larger number of samples, all individuals in this study were born in the same geographic region, and thus it might simply represent a particular HTLV-1 carrier population in which the selective pressure on the p12I sequence would not be occurring. Overall, the significance of natural p12I alleles is unclear, and it is possible that the lysine at position 88 of p12I might have a significant effect on the biological effects of the protein in the host, including giving a possible selective advantage in individuals with a certain MHC I. Future studies including screening of HTLV-1-infected individuals in other populations may elucidate this further.

5. pX ORF II p30II

Earlier studies suggested that ORF II was dispensable for expression of HTLV-1 proteins Tax, Rex, or Env, viral replication and immortalization of primary lymphocytes in vitro (34, 72). In addition, the isolation of a viral clone containing a premature stop codon in pX ORF II, from leukemic cells led to the conclusion that pX ORF II was not necessary for the outgrowth of leukemic clones in vivo (100). However, possible functional role of pX ORF II during early infection was not ruled out by these initial studies. To specifically test the functional role of pX ORF II in viral replication in vivo, we inoculated rabbits with lethally irradiated cell lines expressing the wild-type molecular clone of HTLV-1 (ACH) and a clone containing selected mutations in pX ORF II (ACH.p30/13) (39). While all ACH-inoculated rabbits became infected as early as 2 weeks postinoculation, ACH.p30/13-inoculated animals failed to become infected or maintained low proviral copy numbers in their blood leukocytes. These animals also had weak and transient ex vivo p19 antigen production from their PBMC cultures and anti-HTLV-1 antibody titers declined towards the end of the study. Most surprisingly, using quantitative competitive PCR, we demonstrated a dramatically reduced (up to 100-fold) viral load in the ACH.p30/13-infected animals (39). Taken together, these
Role of accessory proteins of HTLV-1

data suggested that pX ORF II is in fact necessary for maintenance of high viral loads in vivo.

5.1. Biochemical Characteristics of p30II: Features of a Transcription modulator

Several lines of evidence indicate that p30II acts as a transcription factor. Importantly, the protein localizes to the nucleus, specifically the nucleus of cells transiently transfected with a p30II expression vector (29, 41). p30II contains a highly conserved bipartite nuclear localization signal (NLS) between amino acids 71 to 98, which can be functionally substituted for the NLS of Rex (101). In addition, p30II contains serine and threonine-rich regions that share distant homology to the activation domain of cellular transcription factors, such as Oct-1/2, Pit-1, and POU-1 (32) (Figure 2). Taken together, these characteristics suggest that p30II has a role in transcription of viral and cellular gene expression.

5.2. Role of p30II in Modulating HTLV-1 LTR-Mediated Transcription

We have reported that, when provided in limiting concentrations, p30II expression stimulates HTLV-1 LTR-driven reporter gene activity, even in the presence of Tax, whereas higher concentrations represses LTR and CRE-driven reporter gene activity (41). These activities are analogous to herpes simplex virus type 1 (HSV-1) regulation of its immediate-early (IE) gene promoter. VP16, a potent transcription factor from HSV-1, binds the host cell protein HCF, which facilitates the stable complex formation of the viral protein with Oct-1 (102, 103). The IE gene promoter contains an Oct-1-like motif (TAATGARAT) that is important for IE gene expression, with both positive and negative effects, depending on the context of these cellular transcription factors and VP16 (102).

We have also demonstrated that p30II co-localizes with p300 in the nucleus and physically interacts with CREB binding protein (CBP)/p300, at the highly conserved KIX domain, the domain HTLV-1 Tax also interacts with. In addition, p30II is able to disrupt CREB-Tax-CBP/p300 complexes bound to the viral 21-bp Tax Responsive Elements (TRE) repeats (38). To recruit CBP/p300, Tax acts as a high-affinity binding site within this complex (104-106). Once associated with the viral promoter, CBP/p300 is believed to remodel chromatin and/or make communication with the basal transcription machinery possible.

HTLV-1 Tax, a transactivator of LTR mediated transcription, is a key player in the activation of the HTLV-1 viral genes through its interaction with the p300 and CBP coactivators (104, 105, 107, 108). Tax is able to regulate LTR mediated transcription by the recruitment of p300/CBP and P/CAF to these specific sites in the HTLV-LTR promoter (104, 108). Since p30II and Tax interacts with CBP/p300 through the same KIX domain, it is possible that the competitive CBP/p300 binding between p30II and Tax might be the mechanism by which p30II attenuate the formation of these multiprotein complexes and thereby repress transcription on CREB-responsive promoters. Similarly, Tax expression has been demonstrated to interfere with the transcriptional activity of c-Myb and the binding of Tax and c-Myb to KIX domain of CBP was found to be mutually exclusive (109-112).

The coactivators CBP and p300 mediate transcriptional control of various cellular and viral DNA binding transcription factors. Although these coactivators have divergent functions, they are similar in nucleotide sequence, are evolutionarily conserved, and are commonly referred to as CBP/p300 (113, 114). CBP and p300 are highly related and share many functional properties, however there is evidence that these factors are not interchangeable. Several cellular and viral proteins that interact with either CBP or p300 have been identified, including steroid and retinoid hormone receptors, CREB, c-Jun, c-Myb, Sap-1a, c-Fos, MyoD, p53, Stat-1/2, NF-kB, pp90rsk, TATA-binding protein, TFIIIB, HTLV-1 Tax, adenovirus E1A, Kaposi’s sarcoma-associated herpes virus viral interferon regulatory factor protein, and simian virus 40 large T antigen (113-115). CBP/p300 protein is available only at limiting concentrations within the cell nucleus, causing an environment for competition between coactivators and transcription factors, thus providing an additional layer of regulated gene expression (104, 116, 117). There is evidence of a functional antagonistic relationship between transcription factors, as a result of competition for binding to common regions of CBP/p300 (104, 113, 118). Under such a condition of tight competition, relative concentrations of Tax/ p30II at various stages of disease might be a critical factor in determining the levels of viral transcription. We hypothesize that, at higher concentrations, p30II may support viral persistence by reducing viral expression, and thus reducing immune elimination of HTLV-1 infected cells. Additionally, p30II might also repress cellular genes necessary to maintain viral persistence. However, at low concentrations, p30II enhances TRE/viral over CRE/cellular mediated transcription. p30II has the potential to play a role in promoting viral transcription, cell proliferation, competitively repressing CBP/p300-dependent cellular gene transcription (e.g., p53-dependent p21WAF1/CIP1 gene activity), and for promoting the spread of the virus in vivo. This is also consistent with our previous finding that an infectious HTLV-1 molecular clone failed to maintain viral loads in vivo when p30II and p13II expression was abolished (39).

Recently, it was reported that p30II modulates LTR mediated transcription, in the context of the entire provirus, by a post-transcriptional mechanism (V. Franchini personal communication). However, our recent evidence indicates that, the role of CBP/p300 cannot be ruled out in the modulation of LTR mediated transcription by p30II, in the context of the provirus (Michael et al., manuscript in preparation). In the presence of increasing concentrations of p300, we were able to rescue the p30II-mediated repression on LTR driven gene transcription, in a dose-dependent manner, irrespective of the presence or absence of the provirus (Michael et al., manuscript in preparation). CBP and p300 bridge transcription factors to relevant promoters, has intrinsic histone acetyltransferase (HAT)
activity, and form complexes with proteins such as CBP/p300 binding protein-associated factor, which also exhibits HAT activity (113). Recently, there is increasing knowledge of the mechanism and functional significance of the interactions between many viral proteins and CBP/p300. In the case of adenovirus oncoprotein E1A, interaction with CBP/p300 is critical for regulation of transcription, suppression of differentiation, and immortalization of cells in culture (113, 114, 119). The T antigen of SV40 regulates the expression of a group of cellular genes by modifying the HAT activity of CBP/p300 or by bridging the gap between DNA binding transcription factors and components of the general transcription machinery (113, 114). Identifying the molecular mechanism and functional significance of the interaction between p30\textsuperscript{II} and p300 is very crucial in understanding of the role of p30\textsuperscript{II} in the pathogenesis and replication of this important human pathogen. Therefore to further understand the molecular mechanism and functional significance of the interaction between p30\textsuperscript{II} and p300, using N terminal and C terminal deletion mutants of p30\textsuperscript{II}, we have identified the motifs within p30\textsuperscript{II} that are critical in binding CBP/p300 and in regulating LTR mediated transcription, in the presence/ absence of the provirus. Our recent study confirmed the role of p30\textsuperscript{II} as a regulator viral gene transcription, in association with p300. In addition, we identified the amino acid sequence 100-179 of p30\textsuperscript{II} to be the domain critical for its function as a repressor of LTR-mediated transcription, irrespective of the presence or absence of the HTLV-1 provirus (Michael et al., manuscript in preparation). This region contains various important features like DNA binding domain and serine and threonine rich residues with homology to Oct-1 and POU family of transcription factors. Interestingly, there are five lysine residues within this domain, all preceded by at least one serine residue (SK motif), the consensus acetylation sequence, thus representing potential acetylation sites for CBP/p300. Intriguingly, the motif found to be critical for binding p300 is amino acid sequence 1-132 (Michael et al., manuscript in preparation).

It will be important for future studies to define relevant p30\textsuperscript{II} target genes and perhaps yet-unidentified direct p30\textsuperscript{II}-responsive DNA elements. These may include promoters of genes critical for T-cell function, such as the IL-2 promoter, which contains Oct-1-responsive elements (120-123). Further structure-function analyses of p30\textsuperscript{II} will help define the roles of five lysine residues within the domain of p30\textsuperscript{II} critical for repressing LTR mediated transcription. As CBP/p300-mediated acetylation has become a common theme for regulation of protein function, it will be interesting to test whether the intrinsic histone acetyltransferase activity of CBP/p300 can in fact function to acetylate and potentially regulate HTLV-1 p30\textsuperscript{II}.

As of yet, there is little information regarding the relative levels of various HTLV-1 proteins during various stages of the infection. It is possible that differences in expression levels of various viral proteins leading to differences in transcriptional regulation, might be the mechanism by which HTLV-1 infection/ disease progresses through various stages. This is likely to be in synergy with differential regulation of cellular gene regulation by Tax and/or p30\textsuperscript{II} and thus changing the immune responses in accordance with different stages of progression of HTLV-1 infection and disease.

5.3. Role of p30\textsuperscript{II} in Modulating Cellular Gene Transcription

Recently, using recombinant lentivirus expressing p30\textsuperscript{II} in Jurkat T lymphocytes and Affymetrix U133A human gene chip representing ~33000 genes, we demonstrated the role of p30\textsuperscript{II} as a regulator of cellular gene expression. In addition, we identified several potential new functional roles for p30\textsuperscript{II}, in T cell activation or cell signaling and in regulation of apoptosis and cell cycle. More importantly, we illustrated the role of p30\textsuperscript{II} as an activator of many key transcription factors involved in T cell signaling/ activation, such as Nuclear Factor of Activated T cells (NFAT), Nuclear Factor-Kappa B (NF-kB) and Activator Protein-1 (AP-1). Consistent with our previous hypothesis that p30\textsuperscript{II} would modulate immune response, recently we found altered expression of cellular genes involved in immune modulation such as CD46, CD43, CD58, IFN\gamma and CD72 when p30\textsuperscript{II} was expressed (Michael et al., manuscript in preparation).

Our recent findings showed that expression of p30\textsuperscript{II} was associated with altered expression of multiple genes associated with transcription and translation, including transcriptional control genes like TATA-binding protein associated factor 4 (TAF4), homeo box genes, T-box genes, proteins containing helix-loop- helix domain, zinc finger proteins, coiled coil proteins, histone deacetylase-6, nuclear receptor coactivator 3, GAS 7 and translation initiation / elongation factors (Michael et al., manuscript in preparation). Among these, histone deacetylase-6 (124, 125) and nuclear receptor coactivator 3 (CBP interacting protein) (126-128) with histone acetyltransferase and pCAF/CBP recruiting abilities are particularly interesting, since p30\textsuperscript{II} contains multiple highly conserved lysines, which could play a role in acetylation. Another interesting candidate deregulated by p30\textsuperscript{II} was GAS 7, which has sequence homology to Oct and POU family of transcription factors (129). Based on this, p30\textsuperscript{II} appears to regulate transcription through various mechanisms and different levels, some of which could be attributed to the interaction between p30\textsuperscript{II} and CBP/p300.

5.4. Potential Role p30\textsuperscript{II} in T Cell Activation

Our recent findings showed that p30\textsuperscript{II} expression enhanced NFAT, AP-1 and NF-kB mediated transcriptional activity. In addition, expression of p30\textsuperscript{II} was associated with altered expression of multiple genes involved in various stages of T cell activation, including CD28, Vav-2, CD72, CD46, Lck tyrosine kinase, CHP (an endogenous calcineurin inhibitor), c-Jun and c-Fos, protein kinase D, epidermal growth factor, ETS domain transcription factor Elk-1, IKK\gamma, HPK-1, Ras GRP2 and NFAT (Michael et al., manuscript in preparation).

Expression from the IL-2 promoter requires binding of several transcription factors, including NFAT, AP-1 and NF-kB. NFAT is vital to proliferation of
Role of accessory proteins of HTLV-1

Peripheral lymphocytes for HTLV-1 infection (13) while AP-1 is linked to the dysregulated phenotypes of HTLV-1 infected T cells (130) and malignant transformation (131). Activation of AP-1 occurs through Tax-dependent and independent mechanisms in HTLV-1-infected T cells in vitro and in leukemia cells in vivo (130). NF-kB is highly activated in many hematopoietic malignancies, HTLV-1 infected T cell lines and in primary ATL cells, even when Tax expression levels are low (131) and due to its anti-apoptotic activity, it is considered to be a key survival factor for several types of cancer. HTLV-1 p30\textsuperscript{II} is so far the only retroviral accessory protein to have broad modulating activities on the transcriptional activity of NF-kB, NFAT and AP-1.

It will be important for future studies to elucidate the mechanisms employed by p30\textsuperscript{Ii} to enhance NFAT, AP-1 and NF-kB mediated transcription. Interestingly, HTLV-1 p12\textsuperscript{I} stimulates NFAT mediated transcription, when stimulated with PMA, indicating that p12\textsuperscript{I} acts synergistically with Ras/MAPK pathway to promote NFAT activation and thus may facilitate host cell activation and establishment of persistent HTLV-1 infection (36). Since p30\textsuperscript{Ii} enhances NFAT driven transcription significantly when stimulated with ionomycin or CD3 (Michael et al., manuscript submitted), it likely employs a different mechanism than p12\textsuperscript{I}. It is possible that these two accessory proteins act synergistically to modulate NFAT driven transcription and subsequent T cell activation / signaling. AP-1 is able to interact with transcriptional coactivator CBP/p300, as well as viral CREs and mediate HTLV-1 gene expression. NF-kB and NFAT are also known to interact with transcriptional coactivator CBP/p300 (115). Therefore it is possible that p30\textsuperscript{Ii} regulates the transcriptional activity of NFAT, NF-kB and AP-1, at least in part, by its interaction with CBP/p300.

5.5. Genes Modulated p30\textsuperscript{Ii} in Apoptosis, Cell Cycle and Cell Adhesion

HTLV-1 mediated interference with normal T-cell apoptosis is thought to be a mechanism of tumorigenicity, but specific mechanisms by which HTLV-1 infection or any particular HTLV-1 gene products influence on T-cell survival are not fully understood. Similar to the effect of HTLV-1 Tax on apoptosis related genes (24, 132, 133), we have recently used gene array to demonstrate that p30\textsuperscript{Ii} also deregulates multiple genes resulting in pro-apoptotic and anti-apoptotic effects including Bel-2 related/interacting genes, the Fas mediated apoptosis pathway genes, caspases and genes associated with the DNA fragmentation pathway (Michael et al., manuscript in preparation). Since apoptosis is a well-known mechanism of cellular defense against viral infection, a possible role of p30\textsuperscript{Ii} in lymphocyte apoptosis might correlate with the requirement of p30\textsuperscript{Ii} in maintaining proviral loads in vivo (39).

Previous studies indicate that several members of the cell cycle machinery have altered expression in HTLV-1 infected cells (134-137). Several studies examined the aberrations in cell cycle caused by HTLV-1 Tax (134); however, not much is known about the role of other HTLV-1 proteins in causing abnormalities in cell cycle. Our data indicated that p30\textsuperscript{Ii} expression altered the expression of multiple genes involved in regulation of different stages of cell cycle, including checkpoint suppressor 1, histone deacetylase 6, cyclin B1, WEE1 kinase, CDC14A, Lck, JAK2, GAS7, JUN and MDM2 (Michael et al., manuscript in preparation). Some of these genes are particularly interesting, for example, MDM2 is overexpressed in certain leukemias (138) and capable of enhancing the tumorigenic potential of cells by inhibiting p300 / PCAF mediated p53 acetylation (139). We also found that p30\textsuperscript{Ii} expression was associated with altered expression of several genes involved in cell adhesion, including integrins, immunoglobulin (MADCAM1), cadherin, protocadherin, liprin, KIT ligand, CD84 / Ly-9, CD58, CD43 / sialophorin and glycosyl-phosphatidyl-inositol phospholipase D1 (Michael et al., manuscript in preparation).

6. pX ORF II p13\textsuperscript{II}

6.1. Biochemical Characteristics of p13\textsuperscript{II}; Mitochondrial Targeting

Less is known about the function of the smaller protein, p13\textsuperscript{II}, encoded by the 87 carboxy-terminal amino acids of the 241-residue Tof or p30\textsuperscript{Ii} protein. Initial studies demonstrated p13\textsuperscript{II} localization to the nucleus (30), but more-recent reports show mitochondrial localization of the protein (47, 140). Recently, by extraction of mitochondria-enriched fractions, D’Ago et al. demonstrated that full-length p13\textsuperscript{II} is mostly membrane-associated and partly soluble (140). Using electron microscopy, the sub-mitochondrial localization of p13\textsuperscript{II} was further verified to be in the inner mitochondrial membrane and cristae (140). This localization is mediated by an atypical mitochondrial targeting sequence (MTS) in the N terminus of p13\textsuperscript{II} between amino acids 22-31 (Figure 2). The 10-amino-acid MTS also targets green fluorescent protein to mitochondria when fused to the N terminus of green fluorescent protein (47). Importantly, a fusion protein of the p13\textsuperscript{II} MTS with HIV Rev can localize to mitochondria, indicating that the p13\textsuperscript{II} MTS is, at least in part, able to override the potent NLS of Rev (101). While the p13\textsuperscript{II} MTS is also present in p30\textsuperscript{II}, p30\textsuperscript{II} is not localized to the mitochondria, suggesting that the signal has to be near the amino-terminus to direct mitochondrial targeting (141). Analysis of the amino acid sequence of p13\textsuperscript{II} reveals no characteristic DNA-binding motifs and previous data show neither DNA binding nor transcriptional activity (142). Since p30\textsuperscript{II} and p13\textsuperscript{II} are expressed from two different mRNAs and accumulate in separate cellular compartments, it is believed that the two proteins play distinct roles in the viral life cycle, possibly at the level of RNA processing (p30\textsuperscript{II}) and mitochondrial function (p13\textsuperscript{II}) (141).

6.2. p13\textsuperscript{II} Alteration of Mitochondrial Morphology and Inner Membrane Potential

Functionally, expression of p13\textsuperscript{II} disrupts the mitochondrial inner membrane potential and alters mitochondrial morphology and architecture, leading to apparent mitochondrial swelling and fragmentation of their normal interconnected string-like network, suggesting a role for p13\textsuperscript{II} in induction of apoptosis (47). Additionally, it
Role of accessory proteins of HTLV-1

is thought that p13II might possibly cause changes in mitochondrial permeability and/or alter processes like calcium signaling that relies on the mitochondrial network and the endoplasmic reticulum. Intriguingly, proteins that localize to mitochondria have been described for other human viruses including Vpr and Tat of HIV, vMIA of human cytomgalovirus, X of hepatitis B virus and BHFR-1 of Epstein-Barr virus (143-145). The retroviral proteins Vpr and Tat of HIV have been shown to disrupt mitochondrial inner membrane potential, resulting in rapid swelling of mitochondria and release of cytochrome c (145). Lately, mitochondrial swelling and altered permeability due to opening of the permeability transition pore (PTP) have been reported to play a critical role in triggering apoptosis, as demonstrated in the case of HIV-1 Vpr and X of hepatitis B virus (143, 144, 146). However, a study using the p13II amino acid region 9–41 did not show any involvement of the PTP in driven cation fluxes (140). Unlike protein X and Vpr, p13III does not cause substances cytochrome c release (47). The biological significance of p13III mitochondrial localization and disruption of membrane potentials remains unclear.

In cells expressing p13III-GFP fusion protein, only some cells showed apparent mitochondrial swelling and maintained their inner membrane potential, while others had a complete loss of inner membrane potential and marked perinuclear clustering, a characteristic of early apoptosis (47). Based on this, D’Agostino et al. (46) consider that p13III might initially induce selective permeability changes causing swelling and subsequent de-energization and irreversible swelling, and suggested that p13III triggers apoptosis. Despite these observations, thus far, increased levels of apoptosis have never been demonstrated in p13III-expressing cells, leaving open the possibility for other mitochondrion-based functions of this viral protein. Such functions could simply include an increased respiratory activity of mitochondria, which is often accompanied by swelling or Ca2+ signaling and Ca2+ dependent regulation of the oxidative phosphorylation machinery. Thus, p13III may facilitate later stages of HTLV-1 infection such as assembly and release.

A computer prediction program indicated that the amino-terminal portion of p13III was predicted to contain a short hydrophobic leader (amino acids 1–5) followed by an α-helix (amino acids 21–30) that includes the MTS (47). The α-helix includes 4 arginine residues at positions 22, 25, 29, and 30, which are predicted to form a positively charged patch within the putative α-helix, thereby imparting amphipathic properties to this region. D’Agostino et al. (140) demonstrated that amino acids 9–41 of p13III which includes the MTS, folds into an α-helix in the context of a membrane-like environment and has specific effects on the permeability of isolated mitochondria to small cations. Furthermore, the presence of the four arginines in the MTS is essential for the increase in mitochondrial ion conductance and in situ effects on mitochondrial morphology but not for mitochondrial targeting. In addition, circular dichroism analysis illustrated that efficient α-helical folding of amino acids 9–41 of p13III requires the presence of detergent or phospholipid micelles to mimic the membrane environment. This suggests that interaction with or embedding into membranes might be necessary for the correct folding of full-length p13III (140). However, the observation that the p13III MTS is not cleaved upon import into the mitochondria and that it does not require positively charged residues distinguishes it from most MTSs, and suggests that the protein might utilize a mitochondrial import pathway distinct from that described for most MTSs, which involves binding to a series of acidic receptors followed by cleavage of the signal.

6.3. p13III Cellular Protein Interactions

While screening a cDNA library from an HTLV-1-infected rabbit cell line by Saccharomyces cerevisiae two-hybrid assay, Hou et al. (147) discovered the association of p13III with two novel cellular proteins designated C44 and C254. C254 appears to be rabbit actin binding protein 280 (ABP280) present in the cytoskeleton of many different cell types and functions in the modulation of cell shape and polarity and is essential for migration in melanocytes and other cultured cells. More importantly, ABP-280 is important in the insertion of adhesion molecules into the cell membrane. While the region of ABP-280 that interacts with p13III is also involved in interactions with integrin B1, tissue factor, and presenilin, other regions of ABP-280 binds to glycoprotein and the cytoplasmic domain of furin (147). C44 shares homology with archael adenylate kinases, the eukaryotic homologues of which localize to mitochondria and are involved in energy metabolism. Interestingly, the human homologue of C44 is expressed in the Jurkat T-cell line and proliferating, but not resting, PBMC (147). These studies were performed using two molecular clones of HTLV-I, K30p and K34p, which have amino acid differences in pex, p13III, and p30III. Interestingly, only p13III K34, but not p13III K30 allow the interaction with C44. The amino acid sequence of the p13III variant used by Ciminale et al. (47) was most similar to p13III K30, as it had the 25-amino-acid carboxyl tail and that it would not bind C44. This might provide clues to the role of specific amino acids within p13III, which are critical in binding C44 and in causing apoptosis. Additionally, p13III binds to farnesyl pyrophosphate synthetase (FPPS), an enzyme involved in the mevalonate/squalene pathway, and in the synthesis of farnesyl pyrophosphate, a substrate required for prenylation of Ras (53). Interestingly, G4, a mitochondrial targeting accessory protein of BLV also binds to FPPS. Future studies on the functional significance of the interaction between p13III and these cellular proteins will possibly elucidate the role of p13III in altering mitochondrial physiology and thus in HTLV-1 replication and pathogenesis.

Furthermore, Mahana et al. (148), reported an increase in Vav phosphorylation in rabbit cells transfected with an HTLV-1 molecular clone that contains two mutations in pX ORF II, resulting in expression of truncated p13III and p30III. Vav is a hematopoietically restricted guanine nucleotide exchange factor for the Rac/Rho family of GTPases and is necessary for T-cell activation (149). These findings suggest that p13III may play
a role in controlling the activation state of Vav, which may relate to viral infectivity and leukemogenesis.

7. ACCESSORY GENE PRODUCTS OF RELATED DELTARETROVIRUSES

Deltaretroviruses like HTLV-1 HTLV-2, STLV, and BLV have similar genomic structure, viral replication, conserved organizational structure and pathology (13, 150, 151). HTLV-1, HTLV-2 and BLV are complex pathogenic retroviruses of the oncovirinae family that cause lymphoproliferative diseases and encode conserved regulatory and accessory genes from pX region ORFs at the 3’ portion of the viral genome (13). There is increasing knowledge about the role of the homologous gene products in the pathogenesis of HTLV-2 and BLV, after the advent of infectious molecular clones.

HTLV-1 and HTLV-2 are distinct but genetically related viruses that share 60% amino acid identity, yet they differ in their pathogenicity in vivo. HTLV-1 is found mainly in CD4+ T cells, whereas HTLV-2 is mainly in CD8+ T cells in vivo (152). However, both viruses are capable of infecting and transforming T cells in vitro. More importantly, HTLV-2 is also associated with leukemia and neurologic disease, although less frequently than HTLV-1 (7, 153). Analyzing the viral determinants that contribute to the pathogenesis and identifying the similarities and differences between HTLV-1 and -2 may provide a better understanding of HTLV pathogenesis. In addition, HTLV-2 is thought to be an important model to study HTLV pathogenesis, due to the similarities in genome structures and in vitro biological properties. As with HTLV-1, rabbits can be successfully infected with molecular clone of HTLV-2 (154) and although proteins encoded by the pX region between env and the last exon of tax/rex of HTLV-2 appear to be dispensable for viral replication and cellular transformation in vitro (155), they are important for viral replication in the rabbit model (156). Thus, like HTLV-1, proteins encoded in the pX region of HTLV-2 are likely to play an important role in viral life cycle during the natural infection. Further studies will be required to determine the role of these accessory genes in the disease syndromes associated with HTLV-2 infections. Based on initial studies, HTLV-2 ORF I protein p10I and ORF V protein p11V which overlaps the ORF I region appear to be analogous to HTLV-1 p12I in binding MHC-I molecules and perhaps able to down regulate this important surface protein on infected cells (66). Interestingly, p10I localizes within the nucleus (28). However, unlike p12I, p10I and p11I could not bind 16-kDa vacuolar H+ ATPase or the α, β or γ chains of the IL-2R, suggesting that the basic mechanisms of host-virus interaction may be different between HTLV-1 and -2 (66). More strikingly, C-terminal portion of HTLV-1 p30I shares 77.5% sequence homology with the N-terminal 49 amino acids of HTLV-2 ORFII protein p28I (I28). There are recent findings indicating that p30I and p28I can inhibit Tax and Rex function by retaining tax/rex RNA in the nucleus, thus decreasing the doubly spliced RNA pool in the cytoplasm, leading to decrease in Tax and Rex production (V. Franchini and P. Green personal communications).

Bovine leukemia virus infection of sheep offers a reliable model of disease associated with deltaretrovirus infections. The BLV accessory proteins R3 and G4 share varying degrees of homology with the HTLV-1 accessory proteins p12I, p13II and p30I (157). The mRNAs coding for both R3 and G4 were originally identified by RT-PCR in PBMCs from BLV-infected cattle. G4 message is expressed at the beginning of the lymphoproliferative stage of BLV-induced disease while the R3 message is produced during the period surrounding serumconversion (54). Similar to initial reports of HTLV-1 deletion mutants, BLV molecular clones that disrupted the expression of pX ORF genes, encoding the G4 and R3 accessory proteins, failed to influence virus replication and infectivity in cell culture systems but reduced the virus transmission and more importantly the provirus load, leading to a drastic decrease in virus propagation in sheep (54). Importantly, BLV is the closest model system to study apoptotic process since leukemia occurs in vivo in experimental sheep models. Role of HTLV-1 in apoptosis is not clear, since reports are contradictory depending on experimental conditions and an appropriate animal system to elucidate the role of HTLV-1 in the apoptosis is deficient. Interestingly, attenuated mutant proviruses that harbor deletions in the G4 and/or R3 genes decrease the susceptibility of the PBMC to apoptosis and prevent uninfected cells from undergoing programmed cell death at similar levels as that of the wild-type virus, indicating that R3 and G4 genes are not required to maintain both direct and indirect protection against apoptosis in vivo (158). In addition, a live attenuated BLV vaccine with deletions in R3 and G4 genes was found protect 8 out of 9 sheep against a challenge by either wildtype BLV or BLV from blood of infected animals (159).

The BLV G4 protein shares structural features and cellular distribution patterns with HTLV-1 p13I, while BLV R3 appears to be functionally related more closely to HTLV-1 p12I. G4 has 105 amino acids, including an N-terminal stretch of hydrophobic residues (aa 1-24) followed by putative proteolytic cleavage sites and an arginine-rich region (aa 58-72) in the middle while R3 has 44 amino acids, including an N-terminal hydrophilic region followed by hydrophobic sequences. The hydrophilic portion of R3 corresponds to the first 17 amino acids of Rex, which include the domain responsible for accumulation of the protein in the nucleus and in binding to its RNA target, the Rex-responsive element (157). Like p12I, R3 accumulates in the cellular endomembranes. However, since it also accumulates in the nucleus consistent with the presence of the Rex NLS at the N-terminal, it is speculated to regulate post-transcriptional activity of Rex (52). On the other hand, like p13I, G4 also contain a mitochondrial targeting signal and amphipathic α helix. G4 contain 3 helical segments; a long helix lying in the hydrophobic region (aa 8 to 22), another long helix at the second lying near the C-terminus (aa 76 to 89) and an amphipathic short helix in the arginine rich region (aa 63 to 69), among which the first and the last are required for mitochondrial targeting. Importantly, like p13I, G4 also localize to the nucleus and mitochondria (53). To test the functional properties of the viral proteins
Role of accessory proteins of HTLV-1

Table 1. Summary of the functional role of HTLV-1 accessory proteins

<table>
<thead>
<tr>
<th>Protein</th>
<th>pX ORF</th>
<th>Subcellular localization</th>
<th>In vitro functional activity</th>
<th>In vivo effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>p12I</td>
<td>I</td>
<td>ER and cis-Golgi</td>
<td>Induces release of calcium from ER, interact with calceinurin as well as calreticulin and cause calcium-mediated NFAT activation; decreases IL-2 requirement for T-cell activation; enhances the production of IL-2; decreases MHC-1 surface expression</td>
<td>Abolished infectivity in rabbit model; reduced infectivity in non-dividing primary human T-cells</td>
</tr>
<tr>
<td>p27II</td>
<td>II</td>
<td>Nucleus</td>
<td>Binds p300/CBP; differentially modulates HTLV-1 LTR mediated transcription; enhances transcription NFAT, NF-xB and AP-1 mediated transcription.</td>
<td>Unknown, However, recognized by CTLs of infected subjects,</td>
</tr>
<tr>
<td>p30II</td>
<td>II</td>
<td>Nucleus</td>
<td>Mitochondrial swelling and disruption of Δψ</td>
<td>Reduced viral load in rabbit model1</td>
</tr>
<tr>
<td>p13II</td>
<td>II</td>
<td>Mitochondria</td>
<td>Reduced viral load in rabbit model1</td>
<td></td>
</tr>
</tbody>
</table>

1Based on the reduced viral load from ACH.30/13 double-knockout proviral clone in rabbit model of infection (39, Bartoe et al. 2000)

further, Kerkhofs et al. (51) tested the oncogenic potential of R3 and G4, by determining their ability to transform primary rat embryo fibroblasts. In this system, G4 (analogous to HTLV-1 p12I), but not R3 (analogous to HTLV-1 p12I) cooperated with the Ha-ras oncogene to induce tumors in nude mice. Using yeast two-hybrid system and confocal microscopy, G4 was demonstrated to interact with farnesyl pyrophosphate (FPP) synthetase, an enzyme in the mevalonate/squalene pathway that is critical for synthesis of FPP, a substrate required for prenylation of Ras (52). Interestingly, the arginine rich domain of G4 was found to be important in its oncogenic potential and in interacting with FPPS. Analogously, HTLV-1 p13II was also found to specifically interact with FPP synthetase and to colocalize with G4 in mitochondria. Whether these observations explain the function of G4 and p13II is yet to be determined, however these findings provide new directions for research in the role of these accessory proteins in signal transduction pathways, leading to cell transformation and potential therapeutic approaches to eliminate virus replication. Interestingly, infectious molecular clones of BLV with mutations in gene regions encoding G4 and R3 were limited in their ability to maintain proviral loads in infected sheep (51). More importantly, while wild-type BLV typically produces leukemias and/or lymphomas in the majority of infected sheep during the course of the infection, none out of 13 sheep infected with viruses with mutations in G4 or in R3 and G4 developed disease, indicating that G4 is required for pathogenesis in vivo (51). Whether this diminished pathogenic ability is specifically related to these gene products or a generalized attenuation of replication capacity by the virus has not been resolved. Despite this, the BLV model provides an important system to test the role of the regulatory and accessory genes in the pathogenesis of the deltaretoviruses and in exploring possible vaccine trials.

**8. PERSPECTIVE**

The mechanism of HTLV-1 mediated T cell activation and transformation has been extensively investigated. Most of these studies are focused on Tax, which is known to be a critical transcriptional activator and a key protein in cell transformation. The oncogenic potential of Tax has been demonstrated in animal models, as well as in vitro transformation assays (15, 17, 25). Therefore, Tax apparently may be responsible for many of the required events necessary for HTLV-1-mediated lymphocyte immortalization. Nonetheless, it is uncertain whether Tax aids the virus in establishing persistent infection, a prerequisite for basal transcription of Tax itself. Recent studies demonstrate that expression of the accessory proteins encoded by pX ORFs I and II is critical for efficient HTLV-1 infection in vivo, although potentially dispensable for viral replication under activation conditions in vitro.

Based on recent findings from our own laboratory and others, we propose molecular functions for pX ORF I-encoded p12I and ORF II encoded p30I in HTLV-1-induced T-cell activation (Table 1). While the mechanism of p30I function awaits additional research, p12I function has been established to be calcium-dependent, independent of Tax and possibly occurs before Tax is expressed during a natural infection. However highly activated T cells mediated by expression of p12I and/or p30I likely allow HTLV-1 provirus to integrate into host cell genome and permit the early viral infection. Since Tax is also able to cause T cell activation, it appears to be redundant for HTLV-1 to use multiple proteins to activate T lymphocytes. It is possible that these proteins act coordinately or synergistically. We propose that, by modulating the expression of various HTLV-1 proteins, the virus employs selective use of different viral proteins during different stages of the infection. However, since information on the expression profile of HTLV-1 proteins during different stages of the infection is limited, additional studies designed to test the temporal expression patterns of HTLV-1 regulatory and accessory proteins during viral infection are required to explore this possibility. Additionally, it will be crucial to determine if p12I is present in HTLV-1 viral particles or selectively expressed before viral integration. If p12I is expressed after viral integration and not early in viral infection, it is likely to influence late events, such as viral replication, particle
Role of accessory proteins of HTLV-1

assembly and release. Functional and biological significance of the interaction of p12\(^i\) with calcineurin and the regulatory functions on NFAT transcriptional activity also await further investigation. Additionally, p12\(^i\) may play a role in regulation of cell cycle and apoptosis, since it is able to increase the intracellular calcium like the cellular protein Bcl-2 and modulate NFAT activity. However, p12\(^i\) activates NFAT while Bcl-2 blocks NFAT-induced FasL transcription and retards the G0 to S phase transition (160). Therefore, the mechanism employed by p12\(^i\) and Bcl-2 might be distinct and future studies are necessary to test the possible role of p12\(^i\) in cell cycle progression and apoptosis in T lymphocytes. Understanding the role of p12\(^i\) in HAM/TSP also awaits further investigation.

There is increasing understanding of the functional significance of p30\(^i\) p13\(^i\). Emerging evidence suggests that these proteins may act during later stages of infection to promote viral persistence and potentially aid in virus assembly. Currently, we are evaluating the effect of single p13\(^i\) and p30\(^i\) knockout mutations on the infectivity of HTLV-1 viral clones in vivo. Importantly, recent findings based on microarrays from our laboratory shed light on the possible mechanisms by which p30\(^i\) functions in HTLV-1 pathogenesis and in leukemogenesis. However, based on the clues available from this study, future studies are essential not only to verify the findings, but also to test their functional and biological significance. Additional research is also crucial in elucidating the mechanisms employed by p30\(^i\) to enhance NFAT, AP-1 and NF-κB mediated transcription. Such studies may possibly define additional p30\(^i\) target genes and p30\(^i\)-responsive DNA elements. Interestingly, one of the lysine residues within p30\(^i\) appears to be critical for its ability to inhibit the HTLV-1 LTR mediated transcription, irrespective of the presence or the absence of the provirus (B. Michael, unpublished data). On the light of this finding, our current research focus on the intrinsic histone acetyltransferase activity of CBP/p300, whether CBP/p300 acetylates and potentially regulates HTLV-1 p30\(^i\) via acetylation. In addition, findings from the deletion and site directed mutational analysis are valuable in designing experiments to reintroduce these mutations into infectious molecular clones to test their functional significance in vivo.

Little is known about the function of p13\(^i\). Future studies on the p13\(^i\) protein are essential to determine if the mitochondrial swelling induced by p13\(^i\) is significant in apoptosis or viral assembly. Functional significance of the interaction between p13\(^i\) and cellular proteins like FPPS also await additional research. Biological significance of p13\(^i\) mitochondrial localization and disruption of membrane potentials is also uncertain. In vivo experiments using infectious molecular clones with mutations in the motifs critical for the functions in vitro are necessary to determine the biological significance of these findings. Such detailed mutational analyses with each of the accessory proteins will be central in understanding the effect of specific mutations on protein function in the context of the whole virus in vitro or in vivo. In addition to the HTLV-1 rabbit animal model, BLV sheep model can be used to to test specific mutations of analogous gene regions in a disease model.

In conclusion, emerging evidence indicates that the accessory proteins of HTLV-1 and other deltaretroviruses associated with lymphoproliferative diseases, though once thought to be dispensable for viral replication, are in fact multifunctional proteins, critically involved in viral transmission and propagation and may be of potential use in designing therapeutic measures and vaccines.

9. ACKNOWLEDGEMENTS

The authors thank P. Green, K. Boris-Lawrie, T. Rosol, B. Albrecht, and A. Montgomery for their support of the research. We thank T. Voit for illustrations. This work was supported by National Institute of Health grants RR-14324 and CA100730 awarded to Dr. Michael Lairmore; CA-70529 and CA-09338 awarded through the Ohio State University Comprehensive Cancer Center.

10. REFERENCES

8. Szynal, M., Y. Cleuter, T. Beskorowayeh, C. Bagnis, C. Van Lint, P. Kerkhofs, A. Burny, P. Martiat, P. Griebel and B. A. Van den: Disruption of B-cell homeostatic control mediated by the BLV-Tax oncprotein: association with the upregulation of Bcl-2 and signaling through NF-
Role of accessory proteins of HTLV-1


Role of accessory proteins of HTLV-I

Natl Acad Sci USA 89, 3005-3009 (1992)


Role of accessory proteins of HTLV-1


75. Wu, Y. and J. W. Marsh: Selective transcription and
Role of accessory proteins of HTLV-1


79. Aiken, C: Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity. Virology 248, 139-147 (1998)


87. Saksela, K., G. Cheng and D. Baltimore: Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J 14, 484-491 (1995)


100. Chou, K.S., A. Okayama, N. Tachibana, T. H. Lee and M. Essex: Nucleotide sequence analysis of a full-length
Role of accessory proteins of HTLV-1


119. Vandel, L. and D. Trouche: Physical association between the histone acetyl transferase CBP and a histone methyl transferase. EMBO rep 2, 21-26 (2001)


123. Varga, G., U. Dreikhausen, M. Kracht, A. Appel, K. Resch and M. Szamel: Molecular mechanisms of T lymphocyte activation: convergence of T cell antigen
Role of accessory proteins of HTLV-1

receptor and IL-1 receptor-induced signaling at the level of IL-2 gene transcription. *Int Immunol* 11, 1851-1862 (1999)


148. Mahana, W., T. M. Zhao, R. Teller, M. A. Robinson and T. J. Kindt: Genes in the pX region of human T cell


